Generic Name and Formulations:
Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.
Marathon Pharmaceuticals, LLC
Indications for ZINGO:
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Adults and Children:
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Additive effects with other local anesthetics.
Local anesthetic (amide-type).
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Single-use device (disposable, needle-free)—12
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- Spiriva Respimat Gains Indication and New Dosage Strength
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- New Study Proposes Strategies for Pain Control After Total Knee Replacement
- CDC: Novel Lyme Disease Pathogen Discovered
- FDA to Review Rexulti as Maintenance Therapy for Schizophrenia
- Case Illustrates Impact of Dabigatran-Phenytoin Interaction
- Real-World Data on Retreating HCV Patients With NS5A Inhibitor Failure